Overall, our data point towards the idea that SAMHD1 may play a role as a surrogate biomarker of BC prognosis, defined by its capacity to modulate innate immune response, through a process in which the chaperone complex TCP1 plays a key role. The gene discussed is TCP1; the disease is breast cancer.